Literature DB >> 22464889

Arteriolar lesions in renal transplant biopsies: prevalence, progression, and clinical significance.

Verena Bröcker1, Victoria Schubert, Irina Scheffner, Anke Schwarz, Marcus Hiss, Jan Ulrich Becker, Ralph Scherer, Hermann Haller, Hans Heinrich Kreipe, Michael Mengel, Wilfried Gwinner.   

Abstract

Arteriolar hyalinosis in kidney transplants is considered the histopathologic hallmark of chronic calcineurin inhibitor (CNI) toxicity. However, the lesion is not specific. We assessed prevalence, progression, and clinical significance of arteriolar lesions in 1239 renal transplant sequential protocol biopsy samples and 408 biopsy for cause samples in 526 patients. Associations between arteriolar lesions and presumed risk factors, concomitant histopathologic lesions, demographic factors, and graft function were evaluated. The frequency of arteriolar lesions was stable during the first 2 years after transplantation, and increased thereafter (14.8% at 6 months versus 48.6% at >2 years; P < 0.0001). We were unable to find associations with diabetes, hypertension, or CNI therapy. However, patients with early arteriolar lesions received grafts from older donors (mean ± SD age, 54.4 ± 13.4 years versus 43.1 ± 16.6 years; P < 0.0001), and had inferior graft function (estimated glomerular filtration rate 55 ± 21 mL/min versus 63 ± 24 mL/min at 6 weeks, 53 ± 19 mL/min versus 60 ± 23 mL/min at 1 year, and 49 ± 19 mL/min versus 59 ± 22 mL/min at 2 years; P < 0.05). Evaluation of late biopsy samples from patients not receiving CNI therapy revealed a high prevalence of AH without clear-cut identifiable underlying cause. Reproducibility of arteriolar lesions was at best moderate (κ ≤ 0.62). Sampling error in sequential biopsy samples was frequent. In conclusion, in samples from sequential protocol biopsies and biopsies for cause in individual patients, arteriolar lesions in renal transplants not only increase over time without being specific for CNI toxicity but are affected by sampling error and limited reproducibility.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22464889     DOI: 10.1016/j.ajpath.2012.01.038

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  6 in total

Review 1.  Histopathological diagnosis of acute and chronic rejection in pediatric kidney transplantation.

Authors:  Verena Bröcker; Michael Mengel
Journal:  Pediatr Nephrol       Date:  2013-10-19       Impact factor: 3.714

2.  Evaluation of Expanded Criteria Donors Using the Kidney Donor Profile Index and the Preimplantation Renal Biopsy.

Authors:  F Villanego; L A Vigara; J M Cazorla; J Naranjo; L Atienza; A M Garcia; M E Montero; M C Minguez; T Garcia; A Mazuecos
Journal:  Transpl Int       Date:  2022-06-06       Impact factor: 3.842

3.  Deceased Donor Procurement Biopsy Practices, Interpretation, and Histology-Based Decision-Making: A Survey of US Kidney Transplant Centers.

Authors:  Krista L Lentine; Vidya A Fleetwood; Yasar Caliskan; Henry Randall; Jason R Wellen; Melissa Lichtenberger; Craig Dedert; Richard Rothweiler; Gary Marklin; Diane Brockmeier; Mark A Schnitzler; Syed A Husain; Sumit Mohan; Bertram L Kasiske; Matthew Cooper; Roslyn B Mannon; David A Axelrod
Journal:  Kidney Int Rep       Date:  2022-03-28

Review 4.  Current status of pediatric renal transplant pathology.

Authors:  Jan U Becker
Journal:  Pediatr Nephrol       Date:  2016-05-24       Impact factor: 3.714

5.  En Bloc Cadaver Kidney Transplantation From a 9-Month-Old Donor to an Adult Recipient: Maturation of Glomerular Size and Podocyte in the Recipient.

Authors:  Takashi Hirukawa; Hajime Suzuki; Fumio Niimura; Masafumi Fukagawa; Takatoshi Kakuta
Journal:  Transplant Direct       Date:  2017-01-26

Review 6.  Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis.

Authors:  Tianyi Xia; Sang Zhu; Yan Wen; Shouhong Gao; Mingming Li; Xia Tao; Feng Zhang; Wansheng Chen
Journal:  Drug Des Devel Ther       Date:  2018-02-28       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.